The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.

European Journal of Human Genetics : EJHG
Jennifer A SmithSharon L R Kardia

Abstract

Metabolic response to the triglyceride (TG)-lowering drug, fenofibrate, is shaped by interactions between genetic and environmental factors, yet knowledge regarding the genetic determinants of this response is primarily limited to single-gene effects. Since very low-density lipoprotein (VLDL) is the central carrier of fasting TG, identifying factors that affect both total TG and VLDL-TG response to fenofibrate is critical for predicting individual fenofibrate response. As part of the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study, 688 individuals from 161 families were genotyped for 91 single-nucleotide polymorphisms (SNPs) in 25 genes known to be involved in lipoprotein metabolism. Using generalized estimating equations to control for family structure, we performed linear modeling to investigate whether single SNPs, single covariates, SNP-SNP interactions, and/or SNP-covariate interactions had a significant association with the change in total fasting TG and fasting VLDL-TG after 3 weeks of fenofibrate treatment. A 10-iteration fourfold cross-validation procedure was used to validate significant associations and quantify their predictive abilities. More than one-third of the significant, cross-validated SNP-SN...Continue Reading

References

Jan 1, 1993·Annual Review of Public Health·K Y Liang, S L Zeger
Nov 1, 1995·European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies·A NemethM Huettinger
Jun 1, 1996·Diabetes Research and Clinical Practice·G YoshinoT Kazumi
Oct 25, 1996·The Journal of Biological Chemistry·J W EricksonR A Cerione
Oct 25, 1996·The Journal of Biological Chemistry·X ZhangS P Tam
Apr 4, 1998·The American Journal of Cardiology·E A SteinP Laskarzewski
Nov 10, 1998·Circulation·B StaelsJ C Fruchart
Jan 14, 1999·Critical Reviews in Clinical Laboratory Sciences·T M Mason
Jan 14, 1999·Critical Reviews in Clinical Laboratory Sciences·T C Ooi, D S Ooi
Mar 29, 2000·Journal of Mathematical Psychology·M W Browne
Oct 29, 2000·The American Journal of Cardiology·P Cullen
Nov 4, 2000·The American Journal of Clinical Nutrition·S Q Ye, P O Kwiterovich
Mar 26, 2003·Cardiovascular Drugs and Therapy·Jose M Ordovas
May 6, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Charles F SingSharon L R Kardia
Jun 23, 2004·Biostatistics·Ji Zhu, Trevor Hastie
Oct 16, 2004·Annual Review of Genomics and Human Genetics·Jose M Ordovas, Dolores Corella
Jan 11, 2005·Current Vascular Pharmacology·Vasilis TsimihodimosMoses S Elisaf
Feb 18, 2005·Nature Reviews. Genetics·Joel N Hirschhorn, Mark J Daly
Mar 16, 2005·Current Opinion in Lipidology·Chao-Qiang LaiJose M Ordovas
Apr 6, 2005·Journal of the American College of Cardiology·Paul N HopkinsEliot A Brinton
May 21, 2005·Bioinformatics·Annette M MolinaroRuth M Pfeiffer
Jul 14, 2005·Annual Review of Nutrition·Dolores Corella, Jose M Ordovas
Aug 5, 2005·American Journal of Human Genetics·Duncan C ThomasDavid Duggan
Aug 13, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Rashmi R Shah
Oct 4, 2005·The Journal of Clinical Investigation·Martin Merkel, Joerg Heeren
Apr 6, 2006·Journal of Manipulative and Physiological Therapeutics·Anthony L Rosner
Oct 13, 2006·Bioinformatics·Reagan J KellySharon L R Kardia
Nov 15, 2006·Drugs·Sahar B Hachem, Arshag D Mooradian
Dec 7, 2006·Journal of Computational Biology : a Journal of Computational Molecular Cell Biology·Bart J A MertensA M Deelder
Mar 3, 2007·BMC Genomics·Fenghai DuanRobert B Norgren
Mar 30, 2007·Bioinformatics·Ian A WoodKerrie L Mengersen
Apr 14, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Chao-Qiang LaiJose M Ordovas
Apr 28, 2007·Pharmacotherapy·James M McKenney, Domenic Sica
Apr 28, 2007·Science·UNKNOWN Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical RShaun Purcell

❮ Previous
Next ❯

Citations

Dec 2, 2008·Omics : a Journal of Integrative Biology·Beverly McCabe-SellersJim Kaput
Jun 12, 2013·Pharmacogenomics·Miao Hu, Brian Tomlinson
Dec 16, 2011·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Jocelyn TrottierOlivier Barbier
Jun 28, 2011·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A D Dergunov
Aug 6, 2011·Genetic Epidemiology·Qunyuan ZhangIngrid Borecki
Mar 18, 2020·Pharmacogenomics·John S House, Alison A Motsinger-Reif
Feb 27, 2020·PloS One·Paul T Williams
Jul 25, 2017·Clinical Pharmacology and Therapeutics·Daniel M RotroffUNKNOWN ACCORD/ACCORDion Investigators
Aug 31, 2018·Drugs·Nicola TarantinoNatale Daniele Brunetti
Feb 11, 2021·Personalized Medicine·Brian TomlinsonChristopher Wk Lam
Mar 12, 2009·Current Opinion in Lipidology

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.